In vivo antitumour activity of Britanin against gastric cancer through nuclear factor-κB-mediated immune response.
Keru ShiXinyue LiuGetao DuXiaoxia CaiYonghua ZhanPublished in: The Journal of pharmacy and pharmacology (2020)
Britanin may be a promising candidate for gastric cancer chemotherapy, and its anticancer effect likely depends on an NF-κB-mediated immune response.